[1] ZHANG Hengyao JI Shaoxiu WANG YanyanWEI Yanning YAN Qing BI Ran DANGYuqi,.Clinical Observation on Treatment of New Onset of OverweightType 2 diabetes with Qi Stagnation and PhlegmObstruction by Kaiyu Kuxie Method [J]. Journal of Shaanxi University of Traditional Chinese Medicine, 2023, (01): 48-54. [doi: 2096-1340(2023)01-0048-07]
Clinical Observation on Treatment of New Onset of Overweight
Type 2 diabetes with Qi Stagnation and Phlegm
Obstruction by Kaiyu Kuxie Method
- Article number:
- 10.13424/j.cnki.jsctcm.2023.01.010
- Keywords:
- Key words:Kaiku Kuxie; Overweight; New type 2 diabetes; Qi stagnation and phlegm obstruction; TCM treatment
- ZTFLH:
- R255.4
- Code:
- A
- Abstract:
- Abstract：Objective To evaluate the clinical efficacy of the method of Kaiyu Kuxie in the treatment of newly overweight type 2 diabetes patients with Qi stagnation and phlegm stagnation.Methods 100 newly diagnosed type 2 diabetes patients were enrolled in the study，and randomly divided into the treatment group and the control group，50 patients in each group.Under the intervention of lifestyle，the treatment group took orally the Gansong Jiangtang Granules 9 g/time，3 times/day，and the control group took orally the metformin 500 mg/time，3 times/day.A total of 12 weeks were observed，and the blood glucose，HbA1c，HOMA index and lipid metabolism indexes of the two groups were recorded for statistical analysis.Results (1) There were 83 evaluable samples after the study，43 in the treatment group and 40 in the control group.HbA1c in the treatment group and the control group decreased by 1.14% and 1.34%，FBG decreased by 1.93mmol·L-1 and 2.23 mmol·L-1，and BG decreased by 5.72 mmol·L-1 and 6.56mmol/L at 2h.There were significant differences within the group (P<0.01)，but no significant differences between the groups (P>0.05).(2) The results of insulin release test showed that the blood glucose of the two groups in each period was significantly lower than before (P<0.05)，and the decrease in the 1h PG treatment group was better than that in the control group (P<0.05)，the increase in the 1h INS of the treatment group was better than that in the control group (P<0.05)，and the 3h INS of the two groups was lower than before (P<0.05)，and there was no significant difference between the two groups (P>0.05).(3) The weight，waist circumference and BMI of the two groups decreased significantly after treatment (P<0.01).The decrease of LDL-C in the treatment group and the control group was statistically significant (P<0.05)，and there was no significant difference between the two groups (P>0.05).(4) HOMA-IR and ISI in the two groups were significantly improved (P<0.01)，and there was no difference between the two groups (P>0.05).HOMA-β in the two groups had no significant change compared with that before treatment (P>0.05)，but the improvement in the treatment group was better than that in the control group (P<0.01).(5) The total effective rate of the treatment group was 90.70%，while that of the control group was 77.50%.The treatment group was significantly better than the control group (P<0.01). Conclusion The method of Kaiyu Kuxie in the treatment of newly diagnosed overweight type 2 diabetes (type of Qi stagnation and phlegm stagnation) is equivalent to metformin in controlling blood sugar，reducing weight，improving insulin resistance，and regulating blood lipids，and can significantly improve the TCM syndromes of patients.Abstract：Objective To evaluate the clinical efficacy of the method of Kaiyu Kuxie in the treatment of newly overweight type 2 diabetes patients with Qi stagnation and phlegm stagnation.Methods 100 newly diagnosed type 2 diabetes patients were enrolled in the study，and randomly divided into the treatment group and the control group，50 patients in each group.Under the intervention of lifestyle，the treatment group took orally the Gansong Jiangtang Granules 9 g/time，3 times/day，and the control group took orally the metformin 500 mg/time，3 times/day.A total of 12 weeks were observed，and the blood glucose，HbA1c，HOMA index and lipid metabolism indexes of the two groups were recorded for statistical analysis.Results (1) There were 83 evaluable samples after the study，43 in the treatment group and 40 in the control group.HbA1c in the treatment group and the control group decreased by 1.14% and 1.34%，FBG decreased by 1.93mmol·L-1 and 2.23 mmol·L-1，and BG decreased by 5.72 mmol·L-1 and 6.56mmol/L at 2h.There were significant differences within the group (P<0.01)，but no significant differences between the groups (P>0.05).(2) The results of insulin release test showed that the blood glucose of the two groups in each period was significantly lower than before (P<0.05)，and the decrease in the 1h PG treatment group was better than that in the control group (P<0.05)，the increase in the 1h INS of the treatment group was better than that in the control group (P<0.05)，and the 3h INS of the two groups was lower than before (P<0.05)，and there was no significant difference between the two groups (P>0.05).(3) The weight，waist circumference and BMI of the two groups decreased significantly after treatment (P<001).The decrease of LDLC in the treatment group and the control group was statistically significant (P<0.05)，and there was no significant difference between the two groups (P>0.05).(4) HOMAIR and ISI in the two groups were significantly improved (P<0.01)，and there was no difference between the two groups (P>0.05).HOMAβ in the two groups had no significant change compared with that before treatment (P>0.05)，but the improvement in the treatment group was better than that in the control group (P<0.01).(5) The total effective rate of the treatment group was 9070%，while that of the control group was 77.50%.The treatment group was significantly better than the control group (P<0.01). Conclusion The method of Kaiyu Kuxie in the treatment of newly diagnosed overweight type 2 diabetes (type of Qi stagnation and phlegm stagnation) is equivalent to metformin in controlling blood sugar，reducing weight，improving insulin resistance，and regulating blood lipids，and can significantly improve the TCM syndromes of patients.
References:
［1］Li Y,Teng D,Shi X,et al.Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association:national cross sectional study［J］.BMJ,2020,369:997.
［2］中华医学会糖尿病分会.中国2型糖尿病防治指南（2017版）［J］.中华糖尿病杂志,2018,10(1):4-67.
［3］仝小林,刘喜明,魏军平,等.糖尿病中医防治指南［J］.中国中医药现代远程教育,2011,9(4):148-151.
［4］王静,张进军,金虹,等.“六郁”论治肥胖［J］.陕西中医药大学学报,2021,44(3):45-48.
［5］纪少秀,张恒耀,刘永家.从气病论治代谢综合征探讨［J］.山西中医,2014,30(3):1-3.
［6］杨晓燕,宋宗良,杨伟钦.黄连越鞠丸联合生活方式干预糖尿病前期的临床研究［J］.现代中医药,2011,31（2):25-27.
［7］王明坤,张珊珊.结合辨体论治谈2型糖尿病从湿热论治［J］.现代中医药,2012,32（1):71-72.
［8］牛阳.《回回药方》研究［M］.银川:阳光出版社,2010:311.
［9］王震,崔刚,孙理军.谈痰湿体质糖尿病的发病机理及治疗思路［J］.现代中医药,2010,30（4):57-58.
［10］ Rehman T,Ahmad S.Nardostachys chinensis Batalin:A review of traditional uses,phytochemistry,and pharmacology［J］.Phytother Res,2019,33(10):2622-2648.
［11］胡明娟,唐榆,冯盏盏,等.甘松化学成分的研究［J］中成药,2019,41(7):1597-1601.
［12］袁玲,李静远,黄秀兰.回回甘松饮对糖尿病肾病大鼠肾脏保护作用的实验研究［J］.北京中医药,2013,32(11):873-875.
［13］张义伟,董琳.回药甘松丸子对糖尿病治疗作用的实验研究［J］.宁夏医学杂志,2011,33(12):1141-1142.
［14］AShrafizadeh M,Fekri HS,Ahmadi Z,et al.Therapeutic and biological activities of berberine:The involvement of Nrf2signaling pathway［J］.Cell Biochem,2020,121(2):1575-1585.
［15］Feng R,Zhao ZX,Ma SR,et al.Gut Microbiotaregulated pharmacokinetics of berberine and active Metabolites in Beagle dogs after oral administration［J］.Front Pharmacol,2018,9:214.
［16］赵亚丽.黄连素通过miR204/SIRT1改善糖尿病胰岛β细胞功能损伤的作用机制研究［D］.长春：吉林大学,2019.
［17］Zhao Z,Li M,Li C,et al.Dietary preferences and diabetic risk in China:A largescale nationwide Internet databased study［J］.J Diabetes,2020,12(4):270-278.
［18］柳红芳,郭清华,盛益华,等.胰岛素短期强化联合辛开苦降方治疗初发2型糖尿病的临床研究［J］.中国医药导报,2010,7(8):18-20.
［19］赵昱,周丽波,董柳,等.辛开苦降法治疗肥胖2型糖尿病的临床研究［J］.中华中医药学刊,2007,25(12):2575-2578.
［20］张艳红,张先慧,胡照娟,等.辛开苦降方对初发2型糖尿病KKay小鼠肝脏IRS2/PI3K通路的影响［J］.世界中西医结合杂志,2013,8(11):1099-1102,1106.
［21］陈彦旭,金智生,何流,等.基于肠道菌群失调探讨辛开苦降法治疗糖尿病胃轻瘫［J］.中国中医药信息杂志,2021,28(5):8-11.
［22］倪青,杜立娟,孟祥,等.半夏泻心汤对初诊2型糖尿患者血浆GLP-1的影响初探［J］.北京中医药,2017,36(6):549-551.
［23］闫镛,庞国明,苗明三,等.黄连降糖片治疗2型糖尿病模型大鼠的量效关系研究［J］.时珍国医国药,2018,29(3):562-565.
Memo
基金项目：宁夏自然科学基金项目（2019AAC03280）；宁夏青年科技人才托举工程项目（TJGC2019097）；银川市科技创新重点专项（2021-SF-002）